Healthcare • NASDAQ
According to Zyberno, biote Corp. (BTMD) is a buy opportunity — AVERAGE BUSINESS (53/100) trading at a Margin of Safety of +74.1% against historical owner earnings, with a Brina Gap of +22.9% confirming the market is underestimating its forward growth capacity.
According to Zyberno's DCF model, biote Corp. (BTMD) trades at $1.64 against an estimated intrinsic value per share of $6.33 — a +74.1% Margin of Safety based on Owner Earnings of $29.91M TTM, projected at -13.9% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of +22.9% strengthens the case: based on the company's ROIC (21.2%) and reinvestment rate (119.2%), the business can fundamentally grow at 25.3% — but the current enterprise value implies the market expects 2.4%. This places BTMD in the Double Discount quadrant of the Brina Matrix, the rarest and most attractive position. Zyberno's model translates this into a 5-year expected return of 14.9% annually.
Over the trailing twelve months, BTMD generated $29.91M in Owner Earnings. Capital was deployed as follows: $1.07M returned via share buybacks, $1.44M paid as dividends, $3.75M invested in capital expenditures. Reinvestment rate: 119.2%. Owner Earnings have declined at 13.9% annually over the trailing five years using log-linear regression.